华仁药业股份有限公司 2021 年第一季度报告全文 华仁药业股份有限公司 2021 年第一季度报告 2021 年 04 月 1 华仁药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司负责人杨效东、主管会计工作负责人韩莉萍及会计机构负责人(会计主 管人员)孟祥园声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 1,127,868,965.74 | 240,479,398.95 | 369.01% | | 归属于上市公司股东的净利润（元） | 24,826,733.26 | 5,865,601.69 | 323.26% | | 归属于上市公司股东的扣除非经常性 损益的净利润（元） | 21,402,614.74 | 1,922,627.87 | 1,013.20% | | ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2020, representing a year-on-year increase of 15%[14] - The net profit attributable to shareholders was RMB 150 million, an increase of 10% compared to the previous year[14] - The company's operating revenue for 2020 was ¥1,616,318,827.74, representing a 10.56% increase compared to ¥1,461,940,624.48 in 2019[19] - The net profit attributable to shareholders in 2020 was ¥94,623,997.60, a significant increase of 124.94% from ¥42,066,213.53 in 2019[19] - The total profit reached 111.64 million yuan, up 65.61% compared to the previous year[49] - The company achieved a revenue growth of 18% for the next fiscal year, driven by new product launches and market expansion efforts[14] - The sales net profit margin for 2020 was 6%[49] - The company reported a significant increase in revenue from Qingdao Huaren Pharmaceutical Co., Ltd., with total revenue of 241,844,230 CNY and a net profit of 30,211,869 CNY[96] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.15 per 10 shares, totaling approximately RMB 17.8 million[6] - The company distributed cash dividends of 0.15 RMB per share, totaling 17,733,194.73 RMB, representing 18.74% of the net profit for 2020[119] - The profit distribution plan for 2020 was approved, with no stock dividends or capital reserve transfers, indicating a focus on cash returns to shareholders[119] - The company has implemented a cash dividend policy to ensure shareholder returns while maintaining a stable financial policy[159] Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[14] - The company is actively expanding its medical packaging and cardboard box product lines to enhance its pharmaceutical health strategy[30] - The company is positioned to benefit from the ongoing reforms in medical insurance and the promotion of "Internet+" healthcare services, which are expected to enhance service delivery and accessibility[41] - The company aims to enhance its product capabilities and expand into the medical services sector as part of its strategic development plan[102] Acquisitions and Investments - Strategic acquisitions are planned, with a budget of RMB 300 million to enhance the company's product portfolio and distribution channels[14] - The company completed the acquisition of 100% equity in Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pu Bei County Xinke Pharmaceutical Packaging Co., Ltd. in 2020[33] - The acquisition of Guangxi Yuyuan and Pubei Xinke was completed in November 2020, enhancing the company's product range and market coverage[171] - The company has undergone several acquisitions and restructurings, including the acquisition of 100% of the equity of Pubei Xinke Pharmaceutical Packaging Co., Ltd.[98] Research and Development - The company has allocated RMB 50 million for research and development in new technologies for drug delivery systems[14] - The company launched 46 R&D projects in 2020, including 18 pharmaceutical projects and 14 medical device projects[51] - The company obtained 37 new patents during the reporting period, including 8 invention patents, bringing the total to 401 patents by the end of the period[53] - The company has developed a mixed sugar electrolyte injection that meets postoperative patient needs, which has received a registration certificate[77] Risk Management - Risk factors identified include regulatory changes and market competition, with strategies in place to mitigate these risks[6] - The company is facing risks from industry policies, market competition, accounts receivable, and rising costs, which could impact its profitability and operational efficiency[106][108] Social Responsibility and Community Engagement - The company donated CNY 1 million to support frontline medical staff in the fight against the pandemic[157] - The company provided 85 tons of medical supplies urgently needed in Wuhan during the pandemic[157] - The company has established a fund totaling 25360.16 yuan to support employees in need, reflecting its commitment to employee welfare[159] - The company has committed to environmental protection by promoting waste classification and resource utilization in its production processes[160] Operational Efficiency and Management - The company has established a comprehensive after-sales service system to enhance customer satisfaction and protect stakeholder rights[160] - The company has a robust supply chain integration and cost control system, which enhances its competitive edge in the market[112] - The company is committed to maintaining a robust management team to navigate market challenges and opportunities[199] Financial Position and Assets - The company's total assets at the end of 2020 were ¥3,415,544,750.98, a 26.02% increase from ¥2,710,265,463.16 at the end of 2019[19] - The company reported a significant increase in accounts receivable due to the rapid growth of its pharmaceutical business, indicating strong sales performance[85] - The company has recorded a total asset value of 414,753,490 CNY, showcasing its growth potential[96] Governance and Compliance - The company guarantees the independence of its financial accounting department and financial decision-making processes[122] - The company has not engaged in any major related party transactions during the reporting period[139] - The company has implemented the new revenue recognition standards starting from January 1, 2020, as mandated by the Ministry of Finance[131]

华仁药业股份有限公司 2020 年第三季度报告全文 华仁药业股份有限公司 2020 年第三季度报告 2020 年 10 月 1 华仁药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨效东、主管会计工作负责人杨效东及会计机构负责人(会计主 管人员)孟祥园声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,874,738,843.55 | | 2,710,265,463.16 | 6.07% | | 归属于上市公司股东的净资产 | 2,218,1 ...

华仁药业股份有限公司 2020 年半年度报告全文 华仁药业股份有限公司 2020 年半年度报告 2020-052 2020 年 08 月 1 华仁药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人杨效东、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)孟祥园声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、行业政策风险 医药行业是受国家政策影响较大的行业之一，产业政策以及国家、地方性 法律法规的变化，将直接影响医药行业的景气程度。同时，医药行业关系国计 民生，从中长期看，伴随着国家经济的稳定增长、医疗保险体系的逐渐完善、 人口老龄化程度的逐年提高，医药行业有望保持持续增长。国家医疗卫生体制 改革加速推进，医保控费、集采降价等新政策密集实施，给整个医药行业带来 较大的变革，市场竞争也将进一步加剧，药品价格仍然存在下降空间，公司也 将面临着行业政策变革带来的诸多风 ...

华仁药业股份有限公司 2020 年第一季度报告全文 华仁药业股份有限公司 2020 年第一季度报告 2020 年 04 月 1 华仁药业股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨效东、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)李明声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业总收入（元） | 240,479,398.95 | 332,837,828.44 | -27.75% | | 归属于上市公司股东的净利润（元） | 5,865,601.69 | 4,90 ...

Financial Performance - The company's operating revenue for 2019 was ¥1,461,940,624.48, representing a 5.64% increase compared to ¥1,383,859,337.97 in 2018[23]. - The net profit attributable to shareholders for 2019 was ¥42,066,213.53, an increase of 8.43% from ¥38,794,837.59 in 2018[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,857,850.50, which is a 28.31% increase from ¥34,182,091.32 in 2018[23]. - The net cash flow from operating activities for 2019 was ¥309,331,524.30, up 21.63% from ¥254,316,028.34 in 2018[23]. - The total assets at the end of 2019 were ¥2,710,265,463.16, a decrease of 13.97% from ¥3,150,370,411.24 at the end of 2018[23]. - The net assets attributable to shareholders at the end of 2019 were ¥2,175,864,995.76, a slight decrease of 0.23% from ¥2,180,792,295.74 at the end of 2018[23]. - The basic earnings per share for 2019 was ¥0.036, reflecting a 6.82% increase from ¥0.0337 in 2018[23]. - The diluted earnings per share for 2019 was also ¥0.036, consistent with the basic earnings per share[23]. - The weighted average return on net assets for 2019 was 1.93%, a slight increase from 1.89% in 2018[23]. - The company achieved a sales revenue of 1.462 billion yuan in 2019, representing a year-on-year growth of 5.64%[40]. Dividend Distribution - The company reported a cash dividend of 0.1 yuan per 10 shares (including tax) based on a total of 1,182,212,982 shares[12]. - The cash dividend for 2019 accounts for 28.10% of the net profit attributable to ordinary shareholders[129]. - The company did not issue any bonus shares or increase capital from reserves during the reporting period[128]. - The cash dividend distribution policy aligns with the company's articles of association and dividend management measures[126]. - The company has maintained a consistent dividend payout strategy over the past three years, with previous dividends of 0.2 RMB and 0.3 RMB per 10 shares in 2017 and 2018, respectively[129]. Market and Competitive Landscape - The company faces significant risks from industry policy changes, including price reductions and increased competition due to government reforms in the pharmaceutical sector[6]. - The company operates in a highly competitive market for large-volume injections, which poses ongoing market competition risks[8]. - The industry is expected to undergo significant changes due to the nationwide promotion of volume-based procurement, impacting pricing structures and competitive dynamics[107]. - The competitive landscape in the pharmaceutical industry is expected to favor companies with scale, cost advantages, and strong R&D capabilities[107]. Research and Development - The company is focusing on research and development investments and technological innovations to enhance profitability and cash flow amidst rising costs and regulatory pressures[10]. - The company has 20+ projects under research, focusing on kidney-related products and advanced medical devices[53]. - The company was recognized as a national intellectual property demonstration enterprise, with 44 new patents granted in 2019, totaling 345 patents by year-end[54]. - The total R&D investment for 2019 was ¥62.70 million, up from ¥56.02 million in 2018[80]. - R&D expenses increased by 11.44% to ¥62.43 million, with R&D investment accounting for 4.29% of operating income[80]. Operational Strategies - The company has implemented a tiered management system for accounts receivable to improve asset efficiency and reduce collection periods[9]. - The company is committed to controlling production costs through supplier development and innovative procurement strategies[10]. - The company is exploring a development model integrating pharmaceutical manufacturing, commercial services, and financial services, with new subsidiaries established for investment and supply chain financial services[60]. - The company plans to phase out unprofitable business units while focusing on the pharmaceutical and medical device sectors under state-owned control[60]. - The company aims to reform its sales model by transitioning from agency to direct sales, enhancing control over terminal channels, and expanding both existing and new markets to ensure stable and rapid growth[112]. Social Responsibility and Compliance - In 2019, the company donated over CNY 1.5 million to various charitable organizations, demonstrating its commitment to social responsibility[172]. - The company has implemented a clean production process and is committed to environmental protection and sustainable development[172]. - The company emphasizes compliance with legal regulations and improving corporate governance to enhance operational standards and investor relations[115]. - The company has established a comprehensive product after-sales service system to protect customer rights[172]. Subsidiaries and Investments - The company has established three production bases in Qingdao, Rizhao, and Xiaogan, focusing on non-PVC soft bag large-volume preparations and raw materials[33]. - In November 2019, the company established Xi'an Huarun Commercial Factoring Co., Ltd. to provide supply chain financial services to medical institutions and suppliers[37]. - The company has established several new subsidiaries, including Qingdao Huaren Enterprise Service Co., Ltd. with a registered capital of 5 million RMB and Xi'an Huaren Health Investment Management Co., Ltd. with a registered capital of 10 million RMB[104][106]. Risk Management - The company is focusing on risk management, particularly regarding industry policy changes, market competition, accounts receivable, rising costs, and the impact of the COVID-19 pandemic on product sales[116][118][119][120][121].

华仁药业股份有限公司 2019 年第三季度报告全文 华仁药业股份有限公司 2019 年第三季度报告 2019-099 2019 年 10 月 1 华仁药业股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨效东、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)李明声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 单位：人民币元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部 | -2,579,961.38 | | | 分） | | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家 | 3,069,760.08 | | | 统一标 ...

证券代码：300110 证券简称：华仁药业 公告编号：2019-087 华仁药业股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载，误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，构建和谐投资者关系，华仁药业 股份有限公司（以下简称"公司"）将参加由青岛证监局、青岛市上市公司协会、 上证所信息网络有限公司共同举办的"2019 年青岛辖区上市公司投资者网上集 体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将在上证所信息网络有限公司提供的平台举行，投资者 可以登录"上证路演中心"网站（http://roadshow.sseinfo.com）或关注微信 公众号：上证路演中心，参与公司本次投资者集体接待日活动，活动时间为 2019 年 9 月 20 日（星期五）下午 15:00 至 17:00。届时公司高级副总裁兼财务总监 王文萍女士、副总裁兼董事会秘书吴聪女士将通过网络在线交流形式与投资者就 公司治理、发展战略、经营状况和可持续发展等投资者关注的问题进行沟通。 欢迎广大投资者积极参与。 特此公告！ 华仁药业股份有限公 ...

Financial Performance - Total revenue for the reporting period reached ¥711,838,648.71, an increase of 9.42% compared to ¥650,579,239.95 in the same period last year[24]. - Net profit attributable to shareholders decreased by 20.99% to ¥12,965,209.42 from ¥16,408,853.38 year-on-year[24]. - Net cash flow from operating activities fell by 65.87% to ¥43,395,384.66, down from ¥127,133,674.25 in the previous year[24]. - Basic earnings per share decreased by 25.17% to ¥0.0110 from ¥0.0147 in the same period last year[24]. - Total assets decreased by 8.69% to ¥2,876,514,215.00 from ¥3,150,370,411.24 at the end of the previous year[24]. - The company reported a net profit margin improvement, with retained earnings increasing to CNY 425,920,394.86 from CNY 412,955,185.44, an increase of approximately 3.45%[147]. - The total comprehensive income for the first half of 2019 was CNY 14,509,170.65, slightly lower than CNY 14,868,004.11 in the first half of 2018[156]. Cost Management - The company reported challenges in controlling production costs due to rising prices of raw materials and logistics, which have been increasing for several consecutive years, further compressing profit margins[8]. - The company is actively developing new suppliers and locking in prices through bulk contracts to control procurement costs amid rising raw material prices[9]. - The company is focusing on technological innovation and production efficiency improvements to mitigate rising production costs[9]. - The company has implemented measures to manage accounts receivable effectively, aiming to improve asset utilization and reduce financial strain[75]. Strategic Initiatives - The company plans to enhance its core competitiveness by adjusting product structure, controlling costs, improving efficiency, and expanding market presence[7]. - The company aims to increase market share by leveraging volume-based procurement as an opportunity for market integration and driving sales growth[7]. - The company is focusing on expanding its market share and developing large customer bases in its core product lines, including peritoneal dialysis solutions and basic infusion products[47]. - The company has signed a cooperation agreement to establish a joint venture for industrial hemp cultivation, marking a strategic expansion into this new sector[48]. - The company is committed to enhancing its research and development efforts, aiming for innovative solutions in the pharmaceutical sector[179]. Market Conditions - In 2019, the company faced risks of product price declines due to ongoing medical reforms, including volume-based procurement and new pricing mechanisms, which may lead to increased industry competition and a decrease in drug prices[7]. - The competitive landscape in the pharmaceutical industry is intensifying due to ongoing healthcare reforms and price control measures, leading to increased industry concentration[38]. - The company anticipates continued pressure on drug prices due to ongoing healthcare reforms, which may lead to increased competition and a need for strategic adjustments[75]. Financial Management - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves for the reporting period[11]. - The company is prioritizing resource allocation to larger, creditworthy customers to enhance cash flow and profitability[10]. - The company’s financial expenses decreased significantly by 32.50% to RMB 14,433,552.40, down from RMB 21,384,353.99 in the previous year[54]. - The company has committed to maintaining a transparent and fair approach in all its dealings, particularly regarding related party transactions[87]. Operational Efficiency - The company has established a new organizational structure with a matrix management model of 5+8+4+34 to enhance operational efficiency and market expansion[51]. - The company has implemented a sales reform strategy, enhancing its sales network and customer management to improve market penetration[43]. - The company maintains a high-quality control standard that exceeds national standards, ensuring product quality and compliance with GMP certification across all production lines[40]. Research and Development - The company is actively pursuing research and development in the nephrology field and large-volume preparations, with several projects currently in the approval process[47]. - Research and development expenses rose by 16.14% to RMB 29,621,088.58, compared to RMB 25,503,709.14 in the prior year[55]. - The company has several products under review, including a 15% compound amino acid injection and a neutral low-calcium peritoneal dialysis solution, which are awaiting production approval[47]. Environmental and Social Responsibility - The company has established two storage facilities for general solid waste and hazardous waste, ensuring compliance with regulations for waste disposal[114]. - In 2018, the company actively participated in poverty alleviation efforts in Anshun, Guizhou, focusing on improving local medical treatment capabilities[118]. - The company conducts annual third-party monitoring of water quality and noise, with results meeting national standards[116]. Corporate Governance - The company reported a commitment to maintain an independent corporate governance structure, ensuring no conflicts of interest with controlled entities[87]. - The company guarantees to minimize related party transactions and ensure they are conducted fairly and transparently[87]. - The company has pledged to cease any production or business activities that may compete with its own operations if it expands its product range[88].

Financial Performance - Total revenue for Q1 2019 was ¥332,837,828.44, an increase of 3.03% compared to ¥323,059,506.48 in the same period last year[10] - Net profit attributable to shareholders was ¥4,907,861.21, representing a significant increase of 116.59% from ¥2,265,926.44 year-on-year[10] - Net profit excluding non-recurring gains and losses was ¥4,813,162.27, up 115.71% from ¥2,231,294.57 in the previous year[10] - Basic earnings per share rose to ¥0.0042, a 90.91% increase compared to ¥0.0022 in the same period last year[10] - Total profit for the quarter was 7.57 million yuan, reflecting a significant growth of 205.84% year-on-year[19] - The company's net profit attributable to shareholders increased by 116.59% compared to the same period last year, reaching 4.91 million yuan[18] - Net profit for Q1 2019 reached CNY 5,426,875.24, a significant increase of 218.5% compared to CNY 1,702,745.99 in Q1 2018[46] - The total comprehensive income for the first quarter was CNY 2,999,429.29, compared to CNY 2,005,249.73 in the previous year, representing an increase of approximately 49.5%[51] Cash Flow and Assets - The net cash flow from operating activities decreased by 44.20% to ¥26,204,945.36 from ¥46,964,978.05 year-on-year[10] - Cash inflow from operating activities totaled CNY 352,159,536.07, up from CNY 343,042,920.51, indicating a rise of about 2.5%[54] - The net cash flow from operating activities decreased to CNY 26,204,945.36 from CNY 46,964,978.05, a decline of approximately 44.3%[54] - Cash outflow from investing activities was CNY 5,439,651.38, slightly down from CNY 5,710,869.32, showing a decrease of about 4.7%[55] - The net cash flow from financing activities was negative CNY 147,450,518.79, compared to a positive CNY 322,003,439.48 in the previous year, indicating a significant change in financing strategy[55] - Total assets at the end of the reporting period were ¥3,053,308,283.36, down 3.08% from ¥3,150,370,411.24 at the end of the previous year[10] - Total current assets decreased to CNY 1,549,773,142.81 from CNY 1,629,698,789.79, a decline of approximately 4.6%[36] - Cash and cash equivalents dropped to CNY 490,546,099.62 from CNY 617,236,220.26, representing a decrease of about 20.5%[35] Shareholder Information - The company reported a total of 49,331 common shareholders at the end of the reporting period[14] - The top three shareholders held a combined 41.84% of the shares, with Guangdong Yongyu Hengfeng Investment Co., Ltd. holding 16.92%[14] Liabilities and Equity - Total liabilities decreased to CNY 794,625,965.52 from CNY 897,114,968.64, a reduction of approximately 11.5%[37] - Short-term borrowings decreased to CNY 563,300,000.00 from CNY 658,200,000.00, a decline of about 14.4%[36] - The company's equity attributable to shareholders increased to CNY 2,185,700,156.95 from CNY 2,180,792,295.74, a slight increase of about 0.2%[38] - The total liabilities decreased to CNY 741,167,100.25 from CNY 777,468,260.27, a reduction of approximately 4.6%[43] - The total equity increased to CNY 2,074,667,439.01 from CNY 2,071,668,009.72, reflecting a slight growth of 0.1%[43] Operational Costs and Expenses - Total operating costs for Q1 2019 were CNY 325,361,222.38, up from CNY 320,776,524.40, reflecting a year-over-year increase of 1.8%[44] - Research and development expenses for Q1 2019 were CNY 16,625,638.47, slightly up from CNY 16,145,676.11, indicating a focus on innovation[44] - Sales expenses increased to CNY 124,844,571.03 from CNY 117,177,210.55, representing a rise of 6.3%[44] - The company reported a decrease in financial expenses from CNY 15,604,543.16 to CNY 7,426,755.95, a reduction of 52.5%[44] - Other income for Q1 2019 was CNY 1,169,233.54, significantly higher than CNY 250,000.00 in the previous year, indicating improved financial performance[44] Future Plans and Risks - The company plans to establish a joint venture in the industrial hemp sector, aiming to build China's first greenhouse planting base for industrial hemp[21] - The company is facing risks from industry policy changes, including the impact of consistent evaluation of generic drugs and centralized procurement policies[22] - The company has decided to postpone the acquisition of Hanhou Cosmetics due to ongoing legal disputes involving the target company[26] Audit Information - The company did not undergo an audit for the first quarter report[61]